MedTrace Logo

Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19)

NCT04376879 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 301

Last updated 2021-09-10

No results posted yet for this study

Summary

One of the main challenges of the health crisis caused by the COVID-19 epidemic is the availability of beds in intensive care units (ICUs) and, more importantly, the need for invasive mechanical ventilation (IVM) because the ICUs are currently reserved for intubated patients.

The experiences of both China and Italy indicate that a certain number of COVID-19 patients will require mechanical ventilation. However, the limited number of resuscitation beds and ventilators requires strict use of these scarce resources. As a significant proportion about 5% to 10%, of patients initially admitted to hospital with COVID-19 will require ventilation, it is essential to anticipate their need for resuscitation to improve the rare resource of beds and ventilator shortages in intensive care units.

The hypothesis of the study is that, in proven or suspected hospitalised and oxygen-requiring COVID-19 patients, an early predictive clinical score, calculated over the three first days of admission may allow for an earlier identification of patients who will require intubation and transfer to an intensive care unit for orotracheal intubation

Conditions

Interventions

OTHER

Data monitoring for 48h within the first 24 hours of admission for COVID-19

The admission variables and those constituting the predictive score (blood pressure, temperature, oxygenotherapy, biological analysis...) will be collected for 48 hours after enrolment (i.e within the first 24 hours of admission )

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Antoine KIMMOUN, MD-PhD · CHRU de NANCY

  • Jean Damien RICARD, MD-PhD · AP-HP, Louis Mourier Hospital

  • Julie JOSSE, PhD · Institut National de Recherche en Informatique et en Automatique

  • Patrick ROSSIGNOL, MD-PhD · CHRU de NANCY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-16
Primary Completion
2021-05-31
Completion
2021-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04376879 on ClinicalTrials.gov